Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target?
- PMID: 20587800
- PMCID: PMC2889753
- DOI: 10.2337/db10-0299
Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target?
Comment on
-
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.Diabetes. 2010 Jul;59(7):1765-70. doi: 10.2337/db09-1414. Epub 2010 Feb 11. Diabetes. 2010. PMID: 20150286 Free PMC article.
References
-
- Unger RH, Orci L: The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975;1:14–16 - PubMed
-
- Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA: Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4053–4059 - PubMed
-
- Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131–2157 - PubMed
-
- Lovshin JA, Drucker DJ: Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262–269 - PubMed
-
- D'Alessio DA, Vahl TP: Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004;286:E882–E890 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical